These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33799284)

  • 21. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience.
    Zanghì A; D'Amico E; Luca M; Ciaorella M; Basile L; Patti F
    Mult Scler Relat Disord; 2020 Nov; 46():102561. PubMed ID: 33045494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
    PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
    Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
    Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study.
    Elser HC; Koch-Henriksen N; Magyari M
    Mult Scler Relat Disord; 2021 Apr; 49():102739. PubMed ID: 33450501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma thiol/disulphide homeostasis changes in patients with relapsing-remitting multiple sclerosis.
    Ozben S; Kucuksayan E; Koseoglu M; Erel O; Neselioglu S; Ozben T
    Int J Clin Pract; 2021 Jul; 75(7):e14241. PubMed ID: 33891773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis.
    Lejeune F; Chatton A; Laplaud DA; Le Page E; Wiertlewski S; Edan G; Kerbrat A; Veillard D; Hamonic S; Jousset N; Le Frère F; Ouallet JC; Brochet B; Ruet A; Foucher Y; Michel L
    J Neurol; 2021 Feb; 268(2):669-679. PubMed ID: 32902734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
    Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
    Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis.
    Tremlett H; van der Mei IA; Pittas F; Blizzard L; Paley G; Mesaros D; Woodbaker R; Nunez M; Dwyer T; Taylor BV; Ponsonby AL
    Neuroepidemiology; 2008; 31(4):271-9. PubMed ID: 18971584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pregnancy and exclusive breastfeeding on multiple sclerosis relapse rate and degree of disability within two years after delivery.
    Ghiasian M; Nouri M; Moghadasi AN; Ghaffari M
    Clin Neurol Neurosurg; 2020 Jul; 194():105829. PubMed ID: 32305825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event.
    Freedman MS; Laks J; Dotan N; Altstock RT; Dukler A; Sindic CJ
    Mult Scler; 2009 Apr; 15(4):422-30. PubMed ID: 19324980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Memory T Cells Blood Counts and High Naïve Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis.
    Canto-Gomes J; Silva CS; Rb-Silva R; Boleixa D; da Silva AM; Cheynier R; Costa P; González-Suárez I; Correia-Neves M; Cerqueira JJ; Nobrega C
    Front Immunol; 2022; 13():901165. PubMed ID: 35711452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.